Arimoclomol maleate (BRX-220)
(Synonyms: BRX-220) 目录号 : GC31103A co-inducer of heat shock proteins
Cas No.:289893-26-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats[1]Male Wistar rats weighing 240-270 g are used. The animals are kept at a constant room temperature of 25°C with a 12 h light-dark cycle, and are allowed free access to water and standard laboratory chow. The rats are fasted 18 h before the end of the experiment. In group B (n=6), 20 mg/kg Arimoclomol (BRX-220) is administered intragastrically, followed by 75 μg/kg CCK subcutaneously three times, after 1, 3, and 5 h. This whole procedure is repeated for 5 d. The animals in group AB (n=6) receive physiological saline intragastrically instead of Arimoclomol, but otherwise the protocol is the same as in group B. The animals are sacrificed by exsanguination through the abdominal aorta 12 h after the last CCK injection. Three untreated rats (A) are killed for HSP60 and 72 determinations. The pancreas is quickly removed, cleaned from fat and lymph nodes, weighed, and frozen at -70°C until use[1]. |
References: [1]. Rakonczay Z Jr, et al. Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats. Free Radic Biol Med. 2002 Jun 15;32(12):1283-92. |
Arimoclomol is a co-inducer of heat shock proteins (Hsps).1,2 It increases pancreatic Hsp60 and Hsp70 levels, decreases malondialdehyde (MDA) and protein carbonyl levels, increases glutathione peroxidase (GPX) activity, and decreases Cu/Zn superoxide dismutase (SOD) activity in a rat model of cholecystokinin (CCK) octapeptide-induced acute pancreatitis when administered at a dose of 20 mg/kg.1 Arimoclomol (10 mg/kg, i.p.) increases spinal cord levels of Hsp70 and Hsp90 and motoneuron survival, decreases disease severity, and increases lifespan in a Cu/Zn SOD mutant (SOD1G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).2
1.Rakonczay, Z., Jr., Iványi, B., Varga, I., et al.Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in ratsFree Radic. Biol. Med.32(12)1283-1292(2002) 2.Kieran, D., Kalmer, B., Dick, J.R.T., et al.Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS miceNat. Med.10(4)402-405(2004)
Cas No. | 289893-26-1 | SDF | |
别名 | BRX-220 | ||
Canonical SMILES | Cl/C(C(C=CC=1)=CN1=O)=N\OC[C@H](O)CN2CCCCC2.OC(/C=C\C(O)=O)=O | ||
分子式 | C18H24ClN3O7 | 分子量 | 429.85 |
溶解度 | DMSO: 250 mg/mL (581.60 mM); Water: 100 mg/mL (232.64 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3264 mL | 11.632 mL | 23.2639 mL |
5 mM | 0.4653 mL | 2.3264 mL | 4.6528 mL |
10 mM | 0.2326 mL | 1.1632 mL | 2.3264 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。